La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Boston Scientific Gestion
Gestion contrôle des critères 3/4
Le PDG Boston Scientific's est Mike Mahoney, nommé en Oct2011, a un mandat de 12.83 ans. La rémunération annuelle totale est $ 18.72M, composée du salaire de 7.5% et des bonus 92.5%, y compris les actions et options de la société. détient directement 0.13% des actions de la société, d'une valeur de $ 149.92M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 8.4 ans et 8.1 ans.
Informations clés
Mike Mahoney
Directeur général
US$18.7m
Rémunération totale
| Pourcentage du salaire du PDG | 7.5% |
| Durée du mandat du directeur général | 12.8yrs |
| Propriété du PDG | 0.1% |
| Durée moyenne d'occupation des postes de direction | 8.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 8.1yrs |
Mises à jour récentes de la gestion
Recent updates
The Strong Earnings Posted By Boston Scientific (NYSE:BSX) Are A Good Indication Of The Strength Of The Business
Aug 08
Boston Scientific Q2 Earnings Preview: Can The Rally Continue?
Jul 17Here's Why We Think Boston Scientific (NYSE:BSX) Is Well Worth Watching
Jul 05Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$2b |
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$670m |
| Jun 30 2018 | n/a | n/a | US$521m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | US$13m | US$1m | US$104m |
Rémunération vs marché: La rémunération totale de Mike ($USD 18.72M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 13.21M ).
Rémunération et revenus: La rémunération de Mike a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Mike Mahoney (59 yo)
12.8yrs
Titularisation
US$18,723,735
Compensation
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 12.8yrs | US$18.72m | 0.13% $ 150.7m | |
| Executive VP & CFO | 10.6yrs | US$5.83m | 0.015% $ 17.6m | |
| Executive VP & Group President of Cardiology | 14.5yrs | US$5.59m | 0.013% $ 15.4m | |
| Executive VP & President of Peripheral Interventions | 11.6yrs | US$3.78m | 0.0019% $ 2.2m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 8.1yrs | US$4.27m | 0.0023% $ 2.7m | |
| Executive Vice President of Global Operations | 2.3yrs | pas de données | 0.0036% $ 4.2m | |
| Senior VP | less than a year | pas de données | 0.00026% $ 301.3k | |
| Senior VP and Chief Information & Digital Officer | 8.7yrs | pas de données | pas de données | |
| Senior VP of Investor Relations | less than a year | pas de données | 0.0026% $ 3.0m | |
| Senior VP | 3.2yrs | pas de données | 0.0023% $ 2.7m | |
| Senior VP of Market Access & Chief Marketing Officer | 3.3yrs | pas de données | pas de données | |
| Executive Vice President of Human Resources | 11.7yrs | pas de données | 0.0027% $ 3.2m |
8.4yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Gestion expérimentée: L'équipe de direction de BSX est chevronnée et expérimentée (ancienneté moyenne 8.4 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Chairman | 11.8yrs | US$18.72m | 0.13% $ 150.7m | |
| Lead Independent Director | 10.4yrs | US$360.00k | 0.0030% $ 3.5m | |
| Independent Director | 8.3yrs | US$335.00k | 0.0033% $ 3.8m | |
| Independent Director | 8.1yrs | US$320.00k | 0.00020% $ 231.7k | |
| Independent Director | 3.2yrs | US$338.75k | 0.0027% $ 3.1m | |
| Director | less than a year | pas de données | pas de données | |
| Director | less than a year | pas de données | 0.00024% $ 278.1k | |
| Independent Director | 9.3yrs | US$326.25k | 0.0043% $ 4.9m | |
| Independent Director | 15.3yrs | US$340.00k | 0.0036% $ 4.1m | |
| Independent Director | 1.2yrs | US$233.23k | 0.00042% $ 486.6k | |
| Independent Director | 1.2yrs | US$233.23k | 0.00027% $ 312.8k |
8.1yrs
Durée moyenne de l'emploi
60.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de BSX sont considérés comme expérimentés (ancienneté moyenne 8.1 ans).